Therapeutic potential of varenicline in neuropsychiatric disorders: insights into its molecular mechanisms
Molecular Biology Reports · 2026
DOI: 10.1007/s11033-026-12921-5 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Biology Reports, 2026. Verfasst von Abdolkarim Talebi Taheri und 3 weiteren Autor:innen. Beteiligte Einrichtung: Students' Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Varenicline, Mental Disorders. Die Arbeit nennt 100 Literaturangaben.
Abstract (Originalsprache)
Neuropsychiatric disorders pose significant health challenges. Current drug therapies are often inadequate, highlighting the urgent need for new and effective treatments. The α4β2 nicotinic receptor has been implicated in the pathophysiology of various neuropsychiatric disorders. In this context, varenicline, its selective agonist, has garnered increasing attention for its potential therapeutic effects across a range of neuropsychiatric conditions. Emerging preclinical evidence suggests that varenicline may exert neuroprotective effects through modulation of pathways that include synaptic plasticity and synaptic proteins, neuroinflammation, microglial activation, apoptosis, and autophagy. However, direct target engagement for many of these pathways has not yet been established. In this review, we provide a comprehensive review of the cellular and molecular mechanisms by which varenicline might be expected to exert therapeutic effects in a range of neuropsychiatric disorders. Most previous reviews of varenicline have concentrated on its use as a smoking cessation aid or on its potential to treat individual diseases. The current review takes a different approach, focusing at the molecular level on the various pathways that are affected in different diseases, and discussing within each section the evidence that currently exists in relation to each of these in studies conducted in rodent models and in clinical trials. The review seeks to provide insight into the potential benefits and drawbacks of using a single compound to treat a variety of disorders, and to highlight areas for future research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Students' Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran.
- Department of Clinical Biochemistry, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
- Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY, 10461, USA.
- Electrophysiology Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.
- Electrophysiology Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran. tamtaji.or@gmail.com.
Zitieren
APA
Talebi Taheri, A., Aschner, M., Rahmati-Dehkordi, F., & Tamtaji, O. R. (2026). Therapeutic potential of varenicline in neuropsychiatric disorders: insights into its molecular mechanisms. Molecular Biology Reports. https://doi.org/10.1007/s11033-026-12921-5
Vancouver
Talebi Taheri A, Aschner M, Rahmati-Dehkordi F, Tamtaji OR. Therapeutic potential of varenicline in neuropsychiatric disorders: insights into its molecular mechanisms. Molecular Biology Reports. 2026. doi:10.1007/s11033-026-12921-5
BibTeX
@article{TalebiTaheri2026,
author = {Talebi Taheri, Abdolkarim and Aschner, Michael and Rahmati-Dehkordi, Fatemeh and Tamtaji, Omid Reza},
title = {Therapeutic potential of varenicline in neuropsychiatric disorders: insights into its molecular mechanisms},
journal = {Molecular Biology Reports},
year = {2026},
doi = {10.1007/s11033-026-12921-5}
}
EUVIMED